BRIEF published on 11/22/2024 at 07:05, 1 day 3 hours ago Vita 34 Reports Revenue Growth and Cash Increase in Q3 2024 Revenue Growth Cash Flow Profitability Market Expansion Cell Banking
PRESS RELEASE published on 11/22/2024 at 07:00, 1 day 3 hours ago Vita 34 continues to show increasing revenue, improved profitability and stronger cash generation in the third quarter of 2024 Vita 34 AG reports revenue growth of 6.3% to EUR 60.3 million, EBITDA up 77.5% in Q3 2024. Positive cash flow and strong performance despite market challenges EBITDA Revenue Growth Market Challenges Cash Flow Vita 34 AG
BRIEF published on 08/30/2024 at 07:05, 2 months 24 days ago Vita 34 AG Sustains Growth in H1 2024, Strongly Boosts Operating Cash Flow Revenue Growth Operating Cash Flow Vita 34 AG EBITDA Increase H1 2024 Results
PRESS RELEASE published on 08/30/2024 at 07:00, 2 months 24 days ago Vita 34 continues positive trend in the first half of 2024 and once again significantly increases operating cash flow Vita 34 AG reports positive first half of 2024 with revenue growth and increased operating cash flow. EBITDA up by 76.4%. Full-year outlook confirmed EBITDA Revenue Growth Operating Cash Flow Vita 34 AG First Half Results
BRIEF published on 08/09/2024 at 17:09, 3 months 13 days ago Subsidiaries of Vita 34 Reach Agreement with US Licensor Vita 34 FamiCordTx PBKM CAR-T Technology Biotechnology Agreement
PRESS RELEASE published on 08/09/2024 at 17:04, 3 months 13 days ago EQS-Adhoc: Subsidiaries of Vita 34 reach agreement with US licensor Vita 34 AG subsidiaries reach agreement with US licensor on CAR-T technology, settling previous lawsuit and securing new know-how licensing agreement Vita 34 AG Agreement Subsidiaries CAR-T Technology US Licensor
BRIEF published on 08/01/2024 at 12:44, 3 months 21 days ago Thomas Pfaadt Appointed as New Chief Financial Officer of Vita 34 AG Chief Financial Officer Finance Management Board Vita 34 AG Thomas Pfaadt
PRESS RELEASE published on 08/01/2024 at 12:39, 3 months 21 days ago Thomas Pfaadt appointed as new Chief Financial Officer of Vita 34 AG Thomas Pfaadt appointed as new CFO of Vita 34 AG, bringing 20+ years of experience. Management Board complete. Vita 34, leading cell bank in Europe, focusing on cell banking and investments in therapies CFO Vita 34 AG Investments Thomas Pfaadt Cell Banking
BRIEF published on 05/31/2024 at 08:38, 5 months 23 days ago Vita 34 Reports Significant Increases in Earnings and Cash Flow EBITDA Revenue Growth Operating Cash Flow Q1 2024 Earnings Vita 34
PRESS RELEASE published on 05/31/2024 at 08:33, 5 months 23 days ago Vita 34 significantly increases earnings and operating cash flow in the first quarter Vita 34 AG reports a significant increase in earnings and operating cash flow in the first quarter of 2024, with revenues up by 3.6% to EUR 18.6 million. EBITDA exceeds EUR 1.5 million Revenues Business Development Earnings Operating Cash Flow Vita 34 AG
Published on 11/22/2024 at 23:55, 10 hours 31 minutes ago Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 10 hours 56 minutes ago Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 11 hours 21 minutes ago Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 11 hours 56 minutes ago Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.
Published on 11/22/2024 at 18:14, 16 hours 12 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 17:53, 16 hours 33 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 17 hours 31 minutes ago EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 18 hours 26 minutes ago Proposed cancellation of admission to trading
Published on 11/21/2024 at 06:58, 2 days 3 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 2 days 15 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 2 days 16 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 2 days 16 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
